EntryPoint Capital LLC Has $483,000 Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

EntryPoint Capital LLC raised its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 475.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 135,797 shares of the company's stock after purchasing an additional 112,210 shares during the period. EntryPoint Capital LLC owned 0.15% of Aquestive Therapeutics worth $483,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. New York State Common Retirement Fund lifted its stake in shares of Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after purchasing an additional 10,700 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Aquestive Therapeutics in the fourth quarter valued at about $69,000. Intech Investment Management LLC acquired a new position in Aquestive Therapeutics during the 3rd quarter worth approximately $90,000. BNP Paribas Financial Markets grew its holdings in Aquestive Therapeutics by 252.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company's stock valued at $94,000 after purchasing an additional 13,481 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in Aquestive Therapeutics in the 4th quarter valued at about $115,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AQST. Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Monday, March 10th. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Lake Street Capital decreased their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Friday, March 7th. Finally, Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $10.57.

Remove Ads

Aquestive Therapeutics Trading Down 5.9 %

Aquestive Therapeutics stock traded down $0.19 during trading hours on Friday, reaching $3.02. 1,128,401 shares of the company were exchanged, compared to its average volume of 1,615,619. The firm has a market cap of $298.59 million, a price-to-earnings ratio of -6.71 and a beta of 2.76. Aquestive Therapeutics, Inc. has a 12 month low of $2.24 and a 12 month high of $5.80. The stock has a 50-day moving average of $2.99 and a 200 day moving average of $3.95.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts' expectations of $13.11 million. As a group, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.